Solid Tumor Testing Market By Type (Genetic Testing, Conventional Testing), By Application (Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, Brain, Thyroid, Liver, Ovarian, Others), By End User (Hospitals, Pharmaceutical and biotechnology companies, Contract research organizations, Academic research institutions): Global Opportunity Analysis and Industry Forecast, 2021-2031

Solid Tumor Testing Market

Solid tumors, also known as solid cancers, is an abnormal growth of cells that do not contain liquid or cysts. These solid tumors can occur as benign (non-cancerous), which means they do not spread to other parts of the body; or can occur as malignant (cancerous) hence having the capability of spreading to other parts of the body if they are not treated promptly.

The Solid Tumor Testing Market Trends are the rise in the prevalence of solid tumors and the rise in the geriatric population that is more vulnerable to solid tumors. For instance, according to a report published by the American Cancer Society in 2022, lung cancer mainly occurs in the geriatric population. Two out of three people diagnosed with lung cancer are 65 or older, while less than 2% are younger than 45. The average age at the time of diagnosis is about 70. Most diseases such as cancers are highly prevalent in the geriatric population. Moreover, growth in demand for personalized medicine also propels the Solid Tumor Testing Market Size in upcoming years.

In addition, discovery and development; launch of various products; strategies among the key players such as acquisition, collaboration, and agreement drive the soliBased and tumor testing market. For instance, in August 2021, Roche announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel, advancing the company's commitment to personalized healthcare through tests that determine which patients are most likely to benefit from specific and targeted therapies. The VENTANA MMR RxDx Panel is the first companion diagnostic test to aid in identifying patients whose solid tumors are deficient in DNA mismatch repair (dMMR). However, the lack of skilled professionals restricts the market growth in the forecast period.

The Solid Tumor Testing Market Analysis is done into type, application, end-user, and region. By type, the market is categorized into genetic testing and conventional testing. The genetic testing segment is further classified into next-generation sequencing (NGS), real-time PCR (RT-PCR), fluorescent In-Situ hybridization (FISH), and fragment analysis. By application, the market is segmented into prostate, breast, colorectal, endometrial, lung, melanoma, brain, thyroid, liver, ovarian, and others (vaginal & vulvar, bladder, cervical, head & neck, and mesothelioma). By end user, the market is categorized into hospitals, pharmaceutical, and biotechnology companies, contract research organizations, and academic research institutions. By region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

On the basis of type, the genetic testing segment accounted for the largest share of the market in 2021. The dominance of this segment can be attributed to the increase in the use of genetic testing in solid tumor testing for the diagnosis of tumors. The same genetic testing segment is expected to witness the highest CAGR during the forecast period, owing to an increase in the advancement of genetic testing products and a rise in awareness regarding genetic testing for the diagnosis of solid tumor.

Based on application, melanoma was the highest Solid Tumor Testing Market Share in 2021, owing to an increase in the prevalence of skin tumors among others across the world. The breast segment is expected to witness the highest CAGR during the forecast period, owing to the prevalence rate of breast cancer being high in the developed regions as compared to the developing regions.

Depending on the end user, the hospitals were the highest revenue contributor to the market in 2021, owing to an increase in the prevalence of tumor cases, and chronic diseases, and a rise in patient admissions. The academic research institutions segment is expected to witness the highest CAGR during the forecast period, owing to an increase in collaboration between research institutes and academic centers for the development validation of tumor kits, conventional testing, and equipment by conducting various laboratory experiments.

North America accounted for a majority of the solid tumor testing market share in 2021 and is anticipated to remain dominant during the forecast period. This is attributed to the rising in several cancer cases, the presence of key players, and advancement in healthcare in the region. For instance, six in ten Americans live with at least one chronic disease, like heart disease and stroke, cancer, or diabetes which are leading causes of death and disability and they are also a leading driver of the healthcare costs in this region.

Asia-Pacific is anticipated to witness lucrative growth, owing to an increase in medical tourism, implementation of new ICT guidelines in Japan, investments, and reforms to modernize China’s healthcare infrastructure, and rapid growth in the healthcare industry in India, supporting the market growth in this region.

By type, the genetic testing segment was the highest contributor to the Solid Tumor Testing Industry in 2021.

By application, melanoma was the highest contributor to the Solid Tumor Testing Industry in 2021.

By end user, the hospital's segment dominated the market in 2021.

 

Overview

The global solid tumor testing market was valued at $ 23,751.4 million in 2021 and is projected to reach $ 46,722.2 million by 2031, registering a CAGR of 7.0% from 2022 to 2031. Solid tumor testing is a procedure used to evaluate the primary tumors and determine the extent/location of any metastases. The tumor testing in turn allows effective treatment options to be considered so that the spread of cancerous cells can be avoided. A tumor is an abnormal clump of cells. When someone has a solid tumor, that means the tumor doesn't contain any liquid or cysts. Solid tumor testing is a valuable technique that is used for the identification and visualization of solid tumors in clinical diagnostics.

In addition, Solid tumors can be tested through genetic testing and conventional testing. In genetic testing, there are various techniques such as next-generation sequencing (NGS), real-time PCR (RT-PCR), fluorescent In-Situ hybridization (FISH), and fragment analysis that are used for the diagnosis of tumors at early stages. In conventional testing, urine and blood tests, computerized tomography (CT) scan, bone scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, ultrasound and X-ray, and biopsy are used for the diagnosis of solid tumors.

The key factors that drive the growth of the market are an increase in the prevalence of the geriatric population that is prone to solid tumors, a rise in the prevalence of solid tumors in the world, and a rise in healthcare expenditure boosts the market growth.

For instance, according to American Cancer Society January 2021, estimated new cancer cases of Female breast (281,550), Uterine cervix (14,480), Colon & rectum (149,500), Uterine corpus (66,570), Lung & bronchus (235,760), Melanoma of the skin (106,110), non-Hodgkin lymphoma (81,560), Prostate (248,530), Urinary bladder (83,730) were diagnosed in 2021 in the U.S. Each year, approximately 4,00,000 children develop cancer. Overall cancer incidence rates, or rates of new cancers, continue to rise slightly in women and children

However, the dearth of skilled professionals restricts the market growth in the forecast period. Moreover, the rise in technological advancements in solid tumor testing, the increase in several type approvals, and the availability of reimbursements for solid tumor testing tests offer lucrative opportunities to the market players operating in the solid tumor testing market.

The global Solid tumor testing market is segmented into type, application, end-user, and region. By type, the market is categorized into genetic testing and conventional testing. The genetic testing segment is further classified into next-generation sequencing (NGS), real-time PCR (RT-PCR), fluorescent In-Situ hybridization (FISH), and fragment analysis. By application, the market is segmented into prostate, breast, colorectal, endometrial, lung, melanoma, brain, thyroid, liver, ovarian, and others (vaginal & vulvar, bladder, cervical, head & neck, and mesothelioma). By end user, the market is categorized into hospitals, pharmaceutical, and biotechnology companies, contract research organizations, and academic research institutions. By region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global Solid tumor testing market are Abbott Laboratories, Agilent Technologies, Biocare Medical, LLC., F. Hoffmann-La Roche Ltd, Illumina, Inc., MedGenome, Myriad Genetics, QIAGEN N.V., Quest Diagnostics, and Thermo Fischer Scientific, Inc

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the solid tumor testing market analysis from 2021 to 2031 to identify the prevailing solid tumor testing market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the solid tumor testing market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes an analysis of the regional as well as global solid tumor testing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Thermo Fisher Scientific, Inc

Scope of Solid Tumor Testing Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Genetic Testing

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.2.4 Genetic Testing Solid Tumor Testing Market by Genetic Test Type

4.2.4.1 Next generation sequencing (NGS) Market size and forecast, by region

4.2.4.2 Real-time PCR (RT-PCR) Market size and forecast, by region

4.2.4.3 Fluorescent In-Situ Hybridization (FISH) Market size and forecast, by region

4.2.4.4 Fragment Analysis Market size and forecast, by region

4.3 Conventional Testing

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Prostate

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.3 Breast

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

5.4 Colorectal

5.4.1 Key market trends, growth factors and opportunities

5.4.2 Market size and forecast, by region

5.4.3 Market analysis by country

5.5 Endometrial

5.5.1 Key market trends, growth factors and opportunities

5.5.2 Market size and forecast, by region

5.5.3 Market analysis by country

5.6 Lung

5.6.1 Key market trends, growth factors and opportunities

5.6.2 Market size and forecast, by region

5.6.3 Market analysis by country

5.7 Melanoma

5.7.1 Key market trends, growth factors and opportunities

5.7.2 Market size and forecast, by region

5.7.3 Market analysis by country

5.8 Brain

5.8.1 Key market trends, growth factors and opportunities

5.8.2 Market size and forecast, by region

5.8.3 Market analysis by country

5.9 Thyroid

5.9.1 Key market trends, growth factors and opportunities

5.9.2 Market size and forecast, by region

5.9.3 Market analysis by country

6.0 Liver

6.0.1 Key market trends, growth factors and opportunities

6.0.2 Market size and forecast, by region

6.0.3 Market analysis by country

6.1 Ovarian

6.1.1 Key market trends, growth factors and opportunities

6.1.2 Market size and forecast, by region

6.1.3 Market analysis by country

6.2 Others

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 Hospitals

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market analysis by country

6.3 Pharmaceutical and biotechnology companies

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market analysis by country

6.4 Contract research organizations

6.4.1 Key market trends, growth factors and opportunities

6.4.2 Market size and forecast, by region

6.4.3 Market analysis by country

6.5 Academic research institutions

6.5.1 Key market trends, growth factors and opportunities

6.5.2 Market size and forecast, by region

6.5.3 Market analysis by country

7.1 Overview

7.1.1 Market size and forecast

7.2 North America

7.2.1 Key trends and opportunities

7.2.2 North America Market size and forecast, by Type

7.2.2.1 North America Genetic Testing Solid Tumor Testing Market by Genetic Test Type

7.2.3 North America Market size and forecast, by Application

7.2.4 North America Market size and forecast, by End User

7.2.5 North America Market size and forecast, by country

7.2.5.1 U.S.

7.2.5.1.1 Market size and forecast, by Type

7.2.5.1.2 Market size and forecast, by Application

7.2.5.1.3 Market size and forecast, by End User

7.2.5.2 Canada

7.2.5.2.1 Market size and forecast, by Type

7.2.5.2.2 Market size and forecast, by Application

7.2.5.2.3 Market size and forecast, by End User

7.2.5.3 Mexico

7.2.5.3.1 Market size and forecast, by Type

7.2.5.3.2 Market size and forecast, by Application

7.2.5.3.3 Market size and forecast, by End User

7.3 Europe

7.3.1 Key trends and opportunities

7.3.2 Europe Market size and forecast, by Type

7.3.2.1 Europe Genetic Testing Solid Tumor Testing Market by Genetic Test Type

7.3.3 Europe Market size and forecast, by Application

7.3.4 Europe Market size and forecast, by End User

7.3.5 Europe Market size and forecast, by country

7.3.5.1 Germany

7.3.5.1.1 Market size and forecast, by Type

7.3.5.1.2 Market size and forecast, by Application

7.3.5.1.3 Market size and forecast, by End User

7.3.5.2 France

7.3.5.2.1 Market size and forecast, by Type

7.3.5.2.2 Market size and forecast, by Application

7.3.5.2.3 Market size and forecast, by End User

7.3.5.3 UK

7.3.5.3.1 Market size and forecast, by Type

7.3.5.3.2 Market size and forecast, by Application

7.3.5.3.3 Market size and forecast, by End User

7.3.5.4 Italy

7.3.5.4.1 Market size and forecast, by Type

7.3.5.4.2 Market size and forecast, by Application

7.3.5.4.3 Market size and forecast, by End User

7.3.5.5 Spain

7.3.5.5.1 Market size and forecast, by Type

7.3.5.5.2 Market size and forecast, by Application

7.3.5.5.3 Market size and forecast, by End User

7.3.5.6 Rest of Europe

7.3.5.6.1 Market size and forecast, by Type

7.3.5.6.2 Market size and forecast, by Application

7.3.5.6.3 Market size and forecast, by End User

7.4 Asia-Pacific

7.4.1 Key trends and opportunities

7.4.2 Asia-Pacific Market size and forecast, by Type

7.4.2.1 Asia-Pacific Genetic Testing Solid Tumor Testing Market by Genetic Test Type

7.4.3 Asia-Pacific Market size and forecast, by Application

7.4.4 Asia-Pacific Market size and forecast, by End User

7.4.5 Asia-Pacific Market size and forecast, by country

7.4.5.1 Japan

7.4.5.1.1 Market size and forecast, by Type

7.4.5.1.2 Market size and forecast, by Application

7.4.5.1.3 Market size and forecast, by End User

7.4.5.2 China

7.4.5.2.1 Market size and forecast, by Type

7.4.5.2.2 Market size and forecast, by Application

7.4.5.2.3 Market size and forecast, by End User

7.4.5.3 Australia

7.4.5.3.1 Market size and forecast, by Type

7.4.5.3.2 Market size and forecast, by Application

7.4.5.3.3 Market size and forecast, by End User

7.4.5.4 India

7.4.5.4.1 Market size and forecast, by Type

7.4.5.4.2 Market size and forecast, by Application

7.4.5.4.3 Market size and forecast, by End User

7.4.5.5 South Korea

7.4.5.5.1 Market size and forecast, by Type

7.4.5.5.2 Market size and forecast, by Application

7.4.5.5.3 Market size and forecast, by End User

7.4.5.6 Rest of Asia-Pacific

7.4.5.6.1 Market size and forecast, by Type

7.4.5.6.2 Market size and forecast, by Application

7.4.5.6.3 Market size and forecast, by End User

7.5 LAMEA

7.5.1 Key trends and opportunities

7.5.2 LAMEA Market size and forecast, by Type

7.5.2.1 LAMEA Genetic Testing Solid Tumor Testing Market by Genetic Test Type

7.5.3 LAMEA Market size and forecast, by Application

7.5.4 LAMEA Market size and forecast, by End User

7.5.5 LAMEA Market size and forecast, by country

7.5.5.1 Brazil

7.5.5.1.1 Market size and forecast, by Type

7.5.5.1.2 Market size and forecast, by Application

7.5.5.1.3 Market size and forecast, by End User

7.5.5.2 Saudi Arabia

7.5.5.2.1 Market size and forecast, by Type

7.5.5.2.2 Market size and forecast, by Application

7.5.5.2.3 Market size and forecast, by End User

7.5.5.3 South Africa

7.5.5.3.1 Market size and forecast, by Type

7.5.5.3.2 Market size and forecast, by Application

7.5.5.3.3 Market size and forecast, by End User

7.5.5.4 Rest of LAMEA

7.5.5.4.1 Market size and forecast, by Type

7.5.5.4.2 Market size and forecast, by Application

7.5.5.4.3 Market size and forecast, by End User

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Key developments

9.1 QIAGEN

9.1.1 Company overview

9.1.2 Company snapshot

9.1.3 Operating business segments

9.1.4 Product portfolio

9.1.5 Business performance

9.1.6 Key strategic moves and developments

9.2 QUEST DIAGNOSTICS INCORPORATED

9.2.1 Company overview

9.2.2 Company snapshot

9.2.3 Operating business segments

9.2.4 Product portfolio

9.2.5 Business performance

9.2.6 Key strategic moves and developments

9.3 Abbott Laboratories

9.3.1 Company overview

9.3.2 Company snapshot

9.3.3 Operating business segments

9.3.4 Product portfolio

9.3.5 Business performance

9.3.6 Key strategic moves and developments

9.4 Agilent Technologies Inc.

9.4.1 Company overview

9.4.2 Company snapshot

9.4.3 Operating business segments

9.4.4 Product portfolio

9.4.5 Business performance

9.4.6 Key strategic moves and developments

9.5 Biocare Medical LLC

9.5.1 Company overview

9.5.2 Company snapshot

9.5.3 Operating business segments

9.5.4 Product portfolio

9.5.5 Business performance

9.5.6 Key strategic moves and developments

9.6 , F. Hoffmann-La Roche AG

9.6.1 Company overview

9.6.2 Company snapshot

9.6.3 Operating business segments

9.6.4 Product portfolio

9.6.5 Business performance

9.6.6 Key strategic moves and developments

9.7 ILLUMINA, INC.

9.7.1 Company overview

9.7.2 Company snapshot

9.7.3 Operating business segments

9.7.4 Product portfolio

9.7.5 Business performance

9.7.6 Key strategic moves and developments

9.8 MedGenome Labs Private Ltd

9.8.1 Company overview

9.8.2 Company snapshot

9.8.3 Operating business segments

9.8.4 Product portfolio

9.8.5 Business performance

9.8.6 Key strategic moves and developments

9.9 MYRIAD GENETICS, INC.

9.9.1 Company overview

9.9.2 Company snapshot

9.9.3 Operating business segments

9.9.4 Product portfolio

9.9.5 Business performance

9.9.6 Key strategic moves and developments

9.10 Thermo Fisher Scientific, Inc.

9.10.1 Company overview

9.10.2 Company snapshot

9.10.3 Operating business segments

9.10.4 Product portfolio

9.10.5 Business performance

9.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 2. SOLID TUMOR TESTING MARKET, FOR GENETIC TESTING, BY REGION, 2021-2031 ($MILLION)

TABLE 3. SOLID TUMOR TESTING MARKET FOR GENETIC TESTING, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 4. GLOBAL GENETIC TESTING SOLID TUMOR TESTING MARKET, BY GENETIC TEST TYPE, 2021-2031 ($MILLION)

TABLE 5. SOLID TUMOR TESTING MARKET, FOR NEXT GENERATION SEQUENCING (NGS), BY REGION, 2021-2031 ($MILLION)

TABLE 6. SOLID TUMOR TESTING MARKET, FOR REAL-TIME PCR (RT-PCR), BY REGION, 2021-2031 ($MILLION)

TABLE 7. SOLID TUMOR TESTING MARKET, FOR FLUORESCENT IN-SITU HYBRIDIZATION (FISH), BY REGION, 2021-2031 ($MILLION)

TABLE 8. SOLID TUMOR TESTING MARKET, FOR FRAGMENT ANALYSIS, BY REGION, 2021-2031 ($MILLION)

TABLE 9. SOLID TUMOR TESTING MARKET, FOR CONVENTIONAL TESTING, BY REGION, 2021-2031 ($MILLION)

TABLE 10. SOLID TUMOR TESTING MARKET FOR CONVENTIONAL TESTING, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 11. GLOBAL SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 12. SOLID TUMOR TESTING MARKET, FOR PROSTATE, BY REGION, 2021-2031 ($MILLION)

TABLE 13. SOLID TUMOR TESTING MARKET FOR PROSTATE, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 14. SOLID TUMOR TESTING MARKET, FOR BREAST, BY REGION, 2021-2031 ($MILLION)

TABLE 15. SOLID TUMOR TESTING MARKET FOR BREAST, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 16. SOLID TUMOR TESTING MARKET, FOR COLORECTAL, BY REGION, 2021-2031 ($MILLION)

TABLE 17. SOLID TUMOR TESTING MARKET FOR COLORECTAL, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 18. SOLID TUMOR TESTING MARKET, FOR ENDOMETRIAL, BY REGION, 2021-2031 ($MILLION)

TABLE 19. SOLID TUMOR TESTING MARKET FOR ENDOMETRIAL, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 20. SOLID TUMOR TESTING MARKET, FOR LUNG, BY REGION, 2021-2031 ($MILLION)

TABLE 21. SOLID TUMOR TESTING MARKET FOR LUNG, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 22. SOLID TUMOR TESTING MARKET, FOR MELANOMA, BY REGION, 2021-2031 ($MILLION)

TABLE 23. SOLID TUMOR TESTING MARKET FOR MELANOMA, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 24. SOLID TUMOR TESTING MARKET, FOR BRAIN, BY REGION, 2021-2031 ($MILLION)

TABLE 25. SOLID TUMOR TESTING MARKET FOR BRAIN, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 26. SOLID TUMOR TESTING MARKET, FOR THYROID, BY REGION, 2021-2031 ($MILLION)

TABLE 27. SOLID TUMOR TESTING MARKET FOR THYROID, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 28. SOLID TUMOR TESTING MARKET, FOR LIVER, BY REGION, 2021-2031 ($MILLION)

TABLE 29. SOLID TUMOR TESTING MARKET FOR LIVER, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 30. SOLID TUMOR TESTING MARKET, FOR OVARIAN, BY REGION, 2021-2031 ($MILLION)

TABLE 31. SOLID TUMOR TESTING MARKET FOR OVARIAN, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 32. SOLID TUMOR TESTING MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)

TABLE 33. SOLID TUMOR TESTING MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 34. GLOBAL SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 35. SOLID TUMOR TESTING MARKET, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)

TABLE 36. SOLID TUMOR TESTING MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 37. SOLID TUMOR TESTING MARKET, FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2031 ($MILLION)

TABLE 38. SOLID TUMOR TESTING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 39. SOLID TUMOR TESTING MARKET, FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021-2031 ($MILLION)

TABLE 40. SOLID TUMOR TESTING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 41. SOLID TUMOR TESTING MARKET, FOR ACADEMIC RESEARCH INSTITUTIONS, BY REGION, 2021-2031 ($MILLION)

TABLE 42. SOLID TUMOR TESTING MARKET FOR ACADEMIC RESEARCH INSTITUTIONS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 43. SOLID TUMOR TESTING MARKET, BY REGION, 2021-2031 ($MILLION)

TABLE 44. NORTH AMERICA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 45. NORTH AMERICA GENETIC TESTING SOLID TUMOR TESTING MARKET, BY GENETIC TEST TYPE, 2021-2031 ($MILLION)

TABLE 46. NORTH AMERICA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 47. NORTH AMERICA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 48. NORTH AMERICA SOLID TUMOR TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 49. U.S. SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 50. U.S. SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 51. U.S. SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 52. CANADA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 53. CANADA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 54. CANADA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 55. MEXICO SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 56. MEXICO SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 57. MEXICO SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 58. EUROPE SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 59. EUROPE GENETIC TESTING SOLID TUMOR TESTING MARKET, BY GENETIC TEST TYPE, 2021-2031 ($MILLION)

TABLE 60. EUROPE SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 61. EUROPE SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 62. EUROPE SOLID TUMOR TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 63. GERMANY SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 64. GERMANY SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 65. GERMANY SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 66. FRANCE SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 67. FRANCE SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 68. FRANCE SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 69. UK SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 70. UK SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 71. UK SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 72. ITALY SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 73. ITALY SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 74. ITALY SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 75. SPAIN SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 76. SPAIN SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 77. SPAIN SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 78. REST OF EUROPE SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 79. REST OF EUROPE SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 80. REST OF EUROPE SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 81. ASIA-PACIFIC SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 82. ASIA-PACIFIC GENETIC TESTING SOLID TUMOR TESTING MARKET, BY GENETIC TEST TYPE, 2021-2031 ($MILLION)

TABLE 83. ASIA-PACIFIC SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 84. ASIA-PACIFIC SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 85. ASIA-PACIFIC SOLID TUMOR TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 86. JAPAN SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 87. JAPAN SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 88. JAPAN SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 89. CHINA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 90. CHINA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 91. CHINA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 92. AUSTRALIA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 93. AUSTRALIA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 94. AUSTRALIA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 95. INDIA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 96. INDIA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 97. INDIA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 98. SOUTH KOREA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 99. SOUTH KOREA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 100. SOUTH KOREA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 101. REST OF ASIA-PACIFIC SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 102. REST OF ASIA-PACIFIC SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 103. REST OF ASIA-PACIFIC SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 104. LAMEA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 105. LAMEA GENETIC TESTING SOLID TUMOR TESTING MARKET, BY GENETIC TEST TYPE, 2021-2031 ($MILLION)

TABLE 106. LAMEA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 107. LAMEA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 108. LAMEA SOLID TUMOR TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 109. BRAZIL SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 110. BRAZIL SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 111. BRAZIL SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 112. SAUDI ARABIA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 113. SAUDI ARABIA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 114. SAUDI ARABIA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 115. SOUTH AFRICA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 116. SOUTH AFRICA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 117. SOUTH AFRICA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 118. REST OF LAMEA SOLID TUMOR TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 119. REST OF LAMEA SOLID TUMOR TESTING MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 120. REST OF LAMEA SOLID TUMOR TESTING MARKET, BY END USER, 2021-2031 ($MILLION)

TABLE 121.QIAGEN: COMPANY SNAPSHOT

TABLE 122.QIAGEN: OPERATING SEGMENTS

TABLE 123.QIAGEN: PRODUCT PORTFOLIO

TABLE 124.QIAGEN: NET SALES,

TABLE 125.QIAGEN: KEY STRATERGIES

TABLE 126.QUEST DIAGNOSTICS INCORPORATED: COMPANY SNAPSHOT

TABLE 127.QUEST DIAGNOSTICS INCORPORATED: OPERATING SEGMENTS

TABLE 128.QUEST DIAGNOSTICS INCORPORATED: PRODUCT PORTFOLIO

TABLE 129.QUEST DIAGNOSTICS INCORPORATED: NET SALES,

TABLE 130.QUEST DIAGNOSTICS INCORPORATED: KEY STRATERGIES

TABLE 131.ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 132.ABBOTT LABORATORIES: OPERATING SEGMENTS

TABLE 133.ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 134.ABBOTT LABORATORIES: NET SALES,

TABLE 135.ABBOTT LABORATORIES: KEY STRATERGIES

TABLE 136.AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT

TABLE 137.AGILENT TECHNOLOGIES INC.: OPERATING SEGMENTS

TABLE 138.AGILENT TECHNOLOGIES INC.: PRODUCT PORTFOLIO

TABLE 139.AGILENT TECHNOLOGIES INC.: NET SALES,

TABLE 140.AGILENT TECHNOLOGIES INC.: KEY STRATERGIES

TABLE 141.BIOCARE MEDICAL LLC: COMPANY SNAPSHOT

TABLE 142.BIOCARE MEDICAL LLC: OPERATING SEGMENTS

TABLE 143.BIOCARE MEDICAL LLC: PRODUCT PORTFOLIO

TABLE 144.BIOCARE MEDICAL LLC: NET SALES,

TABLE 145.BIOCARE MEDICAL LLC: KEY STRATERGIES

TABLE 146., F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT

TABLE 147., F. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS

TABLE 148., F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO

TABLE 149., F. HOFFMANN-LA ROCHE AG: NET SALES,

TABLE 150., F. HOFFMANN-LA ROCHE AG: KEY STRATERGIES

TABLE 151.ILLUMINA, INC.: COMPANY SNAPSHOT

TABLE 152.ILLUMINA, INC.: OPERATING SEGMENTS

TABLE 153.ILLUMINA, INC.: PRODUCT PORTFOLIO

TABLE 154.ILLUMINA, INC.: NET SALES,

TABLE 155.ILLUMINA, INC.: KEY STRATERGIES

TABLE 156.MEDGENOME LABS PRIVATE LTD: COMPANY SNAPSHOT

TABLE 157.MEDGENOME LABS PRIVATE LTD: OPERATING SEGMENTS

TABLE 158.MEDGENOME LABS PRIVATE LTD: PRODUCT PORTFOLIO

TABLE 159.MEDGENOME LABS PRIVATE LTD: NET SALES,

TABLE 160.MEDGENOME LABS PRIVATE LTD: KEY STRATERGIES

TABLE 161.MYRIAD GENETICS, INC.: COMPANY SNAPSHOT

TABLE 162.MYRIAD GENETICS, INC.: OPERATING SEGMENTS

TABLE 163.MYRIAD GENETICS, INC.: PRODUCT PORTFOLIO

TABLE 164.MYRIAD GENETICS, INC.: NET SALES,

TABLE 165.MYRIAD GENETICS, INC.: KEY STRATERGIES

TABLE 166.THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT

TABLE 167.THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS

TABLE 168.THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO

TABLE 169.THERMO FISHER SCIENTIFIC, INC.: NET SALES,

TABLE 170.THERMO FISHER SCIENTIFIC, INC.: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.SOLID TUMOR TESTING MARKET SEGMENTATION

FIGURE 2.SOLID TUMOR TESTING MARKET,2021-2031

FIGURE 3.SOLID TUMOR TESTING MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.SOLID TUMOR TESTING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.SOLID TUMOR TESTING MARKET,BY TYPE,2021(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF GENETIC TESTING SOLID TUMOR TESTING MARKET,2021-2031(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF CONVENTIONAL TESTING SOLID TUMOR TESTING MARKET,2021-2031(%)

FIGURE 15.SOLID TUMOR TESTING MARKET,BY APPLICATION,2021(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF PROSTATE SOLID TUMOR TESTING MARKET,2021-2031(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF BREAST SOLID TUMOR TESTING MARKET,2021-2031(%)

FIGURE 18.COMPARATIVE SHARE ANALYSIS OF COLORECTAL SOLID TUMOR TESTING MARKET,2021-2031(%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ENDOMETRIAL SOLID TUMOR TESTING MARKET,2021-2031(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF LUNG SOLID TUMOR TESTING MARKET,2021-2031(%)

FIGURE 21.COMPARATIVE SHARE ANALYSIS OF MELANOMA SOLID TUMOR TESTING MARKET,2021-2031(%)

FIGURE 22.COMPARATIVE SHARE ANALYSIS OF BRAIN SOLID TUMOR TESTING MARKET,2021-2031(%)

FIGURE 23.COMPARATIVE SHARE ANALYSIS OF THYROID SOLID TUMOR TESTING MARKET,2021-2031(%)

FIGURE 24.COMPARATIVE SHARE ANALYSIS OF LIVER SOLID TUMOR TESTING MARKET,2021-2031(%)

FIGURE 25.COMPARATIVE SHARE ANALYSIS OF OVARIAN SOLID TUMOR TESTING MARKET,2021-2031(%)

FIGURE 26.COMPARATIVE SHARE ANALYSIS OF OTHERS SOLID TUMOR TESTING MARKET,2021-2031(%)

FIGURE 27.SOLID TUMOR TESTING MARKET,BY END USER,2021(%)

FIGURE 28.COMPARATIVE SHARE ANALYSIS OF HOSPITALS SOLID TUMOR TESTING MARKET,2021-2031(%)

FIGURE 29.COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES SOLID TUMOR TESTING MARKET,2021-2031(%)

FIGURE 30.COMPARATIVE SHARE ANALYSIS OF CONTRACT RESEARCH ORGANIZATIONS SOLID TUMOR TESTING MARKET,2021-2031(%)

FIGURE 31.COMPARATIVE SHARE ANALYSIS OF ACADEMIC RESEARCH INSTITUTIONS SOLID TUMOR TESTING MARKET,2021-2031(%)

FIGURE 32.SOLID TUMOR TESTING MARKET BY REGION,2021

FIGURE 33.U.S. SOLID TUMOR TESTING MARKET,2021-2031($MILLION)

FIGURE 34.CANADA SOLID TUMOR TESTING MARKET,2021-2031($MILLION)

FIGURE 35.MEXICO SOLID TUMOR TESTING MARKET,2021-2031($MILLION)

FIGURE 36.GERMANY SOLID TUMOR TESTING MARKET,2021-2031($MILLION)

FIGURE 37.FRANCE SOLID TUMOR TESTING MARKET,2021-2031($MILLION)

FIGURE 38.UK SOLID TUMOR TESTING MARKET,2021-2031($MILLION)

FIGURE 39.ITALY SOLID TUMOR TESTING MARKET,2021-2031($MILLION)

FIGURE 40.SPAIN SOLID TUMOR TESTING MARKET,2021-2031($MILLION)

FIGURE 41.REST OF EUROPE SOLID TUMOR TESTING MARKET,2021-2031($MILLION)

FIGURE 42.JAPAN SOLID TUMOR TESTING MARKET,2021-2031($MILLION)

FIGURE 43.CHINA SOLID TUMOR TESTING MARKET,2021-2031($MILLION)

FIGURE 44.AUSTRALIA SOLID TUMOR TESTING MARKET,2021-2031($MILLION)

FIGURE 45.INDIA SOLID TUMOR TESTING MARKET,2021-2031($MILLION)

FIGURE 46.SOUTH KOREA SOLID TUMOR TESTING MARKET,2021-2031($MILLION)

FIGURE 47.REST OF ASIA-PACIFIC SOLID TUMOR TESTING MARKET,2021-2031($MILLION)

FIGURE 48.BRAZIL SOLID TUMOR TESTING MARKET,2021-2031($MILLION)

FIGURE 49.SAUDI ARABIA SOLID TUMOR TESTING MARKET,2021-2031($MILLION)

FIGURE 50.SOUTH AFRICA SOLID TUMOR TESTING MARKET,2021-2031($MILLION)

FIGURE 51.REST OF LAMEA SOLID TUMOR TESTING MARKET,2021-2031($MILLION)

FIGURE 52. TOP WINNING STRATEGIES, BY YEAR

FIGURE 53. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 54. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 55.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 56.COMPETITIVE DASHBOARD

FIGURE 57.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 58.QIAGEN.: NET SALES ,($MILLION)

FIGURE 59.QUEST DIAGNOSTICS INCORPORATED.: NET SALES ,($MILLION)

FIGURE 60.ABBOTT LABORATORIES.: NET SALES ,($MILLION)

FIGURE 61.AGILENT TECHNOLOGIES INC..: NET SALES ,($MILLION)

FIGURE 62.BIOCARE MEDICAL LLC.: NET SALES ,($MILLION)

FIGURE 63., F. HOFFMANN-LA ROCHE AG.: NET SALES ,($MILLION)

FIGURE 64.ILLUMINA, INC..: NET SALES ,($MILLION)

FIGURE 65.MEDGENOME LABS PRIVATE LTD.: NET SALES ,($MILLION)

FIGURE 66.MYRIAD GENETICS, INC..: NET SALES ,($MILLION)

FIGURE 67.THERMO FISHER SCIENTIFIC, INC..: NET SALES ,($MILLION